IBI302 Eye Injections for Neovascular Age-related Macular Degeneration
Tests IBI302 injections in the eye in people with neovascular age-related macular degeneration.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Where in China
- Shanghai General HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Trial code
- NCT07275840
- Record updated
- 8 January 2026
- Original description
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.Read full original descriptionShow less
An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Inclusion: Have signed an informed consent form before participating in the research; Male or female individuals aged 50 or above at the time of signing the informed consent form; Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea; At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).
Exclusion: According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results; Within 90 days before baseline, the study eye had received anti-VEGF treatment; Within 90 days before baseline, the study eye had received anti-complement treatment; At any time before baseline, the study eye had received IBI302 treatment; There is an active intraocular or periocular infection or inflammation in either eye; The non-study eye has severe visual function disorders; Uncontrollable hypertension; Glycated hemoglobin (HbA1c) > 10.0% within 28 days prior to screening; The study eye has uncontrollable glaucoma; Other exclusion criteria set by protocol.